


# HEALTHCARE CONFERENCE 2024



## Day 1: Monday, 18 November

---

8:55AM INTRODUCTION

---

9:00AM AVITA MEDICAL (AVH)

9:30AM POLYNOVO (PNV)

10:00AM AROA BIOSURGERY (ARX)

---

10:25AM MORNING TEA

---

10:30AM CLINUVEL PHARMACEUTICALS (CUV)

11:00AM ALCIDION (ALC)

11:30AM MEDADVISOR (MDR)

12:00PM BIOME (BIO)

12:30PM LTR PHARMA (LTP)

---

1:00PM STARPHARMA (SPL)

1:30PM COMPUMEDICS (CMP)

2:00PM INOVIQ (IIQ)

2:30PM NANOSONICS (NAN)

---

2:55PM AFTERNOON TEA

---

3:00PM OPTHEA (OPT)

3:30PM PYC THERAPEUTICS (PYC)

4:00PM DIMERIX (DXB)

4:30PM IMPEDIMED (IPD)

5:00PM AVECHO BIOTECHNOLOGY (AVE)

---

5:25PM WRAP-UP

---


Session 1

Session 2

Session 3

Session 4

# HEALTHCARE CONFERENCE 2024



## Day 2: Tuesday, 19 November

8:55AM INTRODUCTION

9:00AM TRAJAN (TRJ)

9:30AM ONEVIEW HEALTHCARE (ONE)

10:00AM QBIOTICS

10:25AM MORNING TEA

10:30AM TELIX PHARMACEUTICALS (TLX)

11:00AM RADIOPHARM THERANOSTICS (RAD)

11:30AM CYCLOPHARM (CYC)

12:00PM CLARITY PHARMACEUTICALS (CU6)

12:30PM ARGENICA THERAPEUTICS (AGN)

1:00PM BOTANIX PHARMACEUTICALS (BOT)

1:30PM SYNTARA (SNT)

2:00PM MICROBA LIFE SCIENCES (MAP)

2:30PM GENETIC SIGNATURES (GSS)

2:55PM AFTERNOON TEA

3:00PM MESOBLAST (MSB)

3:30PM IMUGENE (IMU)

4:00PM PARADIGM BIOPHARMACEUTICALS (PAR)

4:30PM 4DMEDICAL (4DX)

5:00PM DOCTOR CARE ANYWHERE (DOC)

5:25PM WRAP-UP


Session 1

Session 2

Session 3

Session 4

# HEALTHCARE CONFERENCE 2024



## Day 3: Wednesday, 20 November

---

8:55AM INTRODUCTION

---

9:00AM CYNATA THERAPEUTICS (CYP)

9:30AM NEUREN PHARMACEUTICALS (NEU)

10:00AM IMMUTEP (IMM)

Session 1

---

10:25AM MORNING TEA

---

10:30AM MONASH IVF GROUP (MVF)

11:00AM MEDICAL DEVELOPMENTS (MVP)

11:30AM EBR SYSTEMS (EBR)

12:00PM LUMOS DIAGNOSTICS (LDX)

Session 2

---

12:30PM LUNCH

---

1:00PM PRO MEDICUS (PME)

1:30PM EMVISION MEDICAL DEVICES (EMV)

2:00PM AFT PHARMACEUTICALS (AFP)

2:30PM MACH7 TECHNOLOGIES (M7T)

Session 3

---

2:55PM AFTERNOON TEA

---

3:00PM PERCHERON THERAPEUTICS (PER)

3:30PM PROTEOMICS (PIQ)

4:00PM CURVEBEAM AI (CVB)

4:30PM IMMVIRX


Session 4

---

4:55PM WRAP-UP

---

# HEALTHCARE CONFERENCE 2024



**BELL POTTER**

## Day 1: Monday, 18 November

### 9:00AM AVITA MEDICAL (AVH)

Avita Medical is a one technology company – being Recell, also known as autologous skin cell suspension. Recell is a medical device used for the reconstruction of skin in patients with severe (2nd and 3rd degree) burns. Adjacent markets for the product includes trauma wounds, Vitiligo and potentially aesthetic use.

Market cap \$462.7M

### 9:30AM POLYNOVO (PNV)

PolyNovo is a disruptive ASX 200 medical technology company. Its products simplify managing acute complex wounds, redefining healing with differentiated outcomes across many etiologies. After treating 45,000+ patients across 39 countries, the company is investing for growth via new products, indications and markets with a view to treat millions more.

Market cap \$1.4B

### 10:00AM AROA BIOSURGERY (ARX)

Aroa Biosurgery is a high growth soft tissue reconstruction company, engaged in the developing, manufacturing, and selling medical devices for wound and tissue repair using extracellular matrix technology in the United States and internationally.

Market cap \$224.2M

### 10:30AM CLINUVEL PHARMACEUTICALS (CUV)

Clinuvel Pharmaceuticals is a global pharmaceutical company developing and commercialising treatments for patients with a range of serious conditions. The company's lead drug, SCENESSE (afamelanotide), is approved for treating patients with the rare disease Erythropoietic Protoporphyrria (EPP). Beyond EPP, Clinuvel has various active R&D activities underway.


Market cap \$676.3M

### 11:00AM ALCIDION (ALC)

Alcidion's purpose is to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations. Based on the flagship product, Miya Precision, Alcidion's solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings.

Market cap \$75.2M

# HEALTHCARE CONFERENCE 2024



**BELL POTTER**

## Day 1: Monday, 18 November

11:30AM

### **MEDADVISOR (MDR)**

MedAdvisor Solutions is a global leader in patient engagement solutions that help simplify the patient medication journey. MedAdvisor Solutions works with over 34,000 US pharmacies with reach to over two-thirds of the population. In Australia, more than 95% of Australian pharmacies use MedAdvisor Solutions software to improve pharmacy workflow and to connect with patients.

Market cap \$146.1M

12:00PM

### **BIOME (BIO)**

Biome Australia develops, licenses, commercialises and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines, many of which are supported by clinical research. Biome aims to improve health outcomes and quality of life and make its products accessible to all.

Market cap \$141.3M

12:30PM

### **LTR PHARMA (LTP)**

LTR Pharma is a clinical stage biopharmaceutical company, pioneering a novel intranasal technology – SPONTAN® (SDS-089) – designed to treat erectile dysfunction in 10 minutes or less. LTR Pharma is commercialising this 'First in Class' SPONTAN® product with fast-track US NDA Filing within two years.

Market cap \$209.2M

1:00PM

### **STARPHARMA (SPL)**

Starpharma is dedicated to improving health outcomes and quality of life for patients with significant illnesses, including cancer. Starpharma uses its proprietary dendrimer technology to develop innovative pharmaceutical products. Starpharma's portfolio comprises three clinical-stage oncology assets, preclinical radiopharmaceutical and ADC assets, research collaborations, and three commercially marketed products.

Market cap \$43.9M

# HEALTHCARE CONFERENCE 2024



**BELL POTTER**

## Day 1: Monday, 18 November

### 1:30PM **COMPUMEDICS (CMP)**

Compumedics is a global medical technology company focused on: Monitoring and diagnosing sleep disorders - with an emerging SaaS home sleep testing business; Monitoring neurological disorders - with an emerging MEG business; Highly sophisticated brain research; Ultrasonic monitoring of blood flow through the brain - with emerging robotic AI concussion technology.

Market cap \$54.2M

### 2:00PM **INOVIQ (IIQ)**

Inoviq is developing next-generation diagnostics and therapeutics for cancer. Inoviq has commercialised its efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection of ovarian and breast cancers.

Market cap \$50.2M

### 2:30PM **NANOSONICS (NAN)**

Nanosonics' mission is to improve the safety of patients, clinics, and the environment by transforming the way infection prevention practices are understood and conducted, introducing innovative technologies that deliver improved standards of care.


Market cap \$995.0M

### 3:00PM **OPTHEA (OPT)**

Opthea is a clinical-stage biopharmaceutical company developing a novel drug candidate, called sozinibercept, to treat highly prevalent retinal diseases, focusing initially on wet age-related macular degeneration (wet AMD). Sozinibercept is currently being evaluated in two pivotal Phase 3 clinical trials, each comprising ~990 patients and expected to report topline results in 2025.

Market cap \$1.00B

# HEALTHCARE CONFERENCE 2024



**BELL POTTER**

## Day 1: Monday, 18 November

3:30PM

### **PYC THERAPEUTICS (PYC)**

PYC Therapeutics is a clinical-stage biotechnology company developing targeted RNA therapies for patients with rare genetic diseases. The company has four drug candidates in active development, with the lead asset currently undergoing two Phase 1 trials in patients with a rare blinding eye diseases, called Retinitis Pigmentosa Type 11 (RP11).

Market cap \$909.9M

4:00PM

### **DIMERIX (DXB)**

Dimerix is a clinical-stage biopharmaceutical company focussed on developing its lead drug candidate, called DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease. Dimerix is conducting a global, placebo-controlled Phase 3 trial with DMX200 in FSGS patients who are on a stable dose of an angiotensin II receptor blocker (ARB).

Market cap \$217.6M

4:30PM

### **IMPEDIMED (IPD)**

ImpediMed is forging the standard of care for the early detection and monitoring of breast-cancer related lymphoedema with its FDA-cleared and CE Marked bioimpedance spectroscopy technology, supported by a positive global clinical trial, professional guidelines and increasing US payor coverage. ImpediMed is uniquely positioned to accelerate business growth and advance patient outcomes.

Market cap \$113.3M


5:00PM

### **AVECHO BIOTECHNOLOGY (AVE)**

Avecho is an innovation-led biotechnology company developing and commercialising Human and Animal Health products, using a proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from vitamin E using a patented process, proven to enhance the solubility and oral, dermal and transdermal adsorption of drugs and nutrients.

Market cap \$9.5M

# HEALTHCARE CONFERENCE 2024



## Day 2: Tuesday, 19 November

### 9:00AM **TRAJAN (TRJ)**

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Market cap \$179.7M

### 9:30AM **ONEVIEW HEALTHCARE (ONE)**

Oneview Healthcare's vision is to power personalised, exemplary care experiences. Unifying a facility's systems, content and services into one digital platform at the point of care with dedicated touch and TV devices, we help healthcare providers to enable patients and families, deliver virtual care, manage experience and optimise patient flow.

Market cap \$216.6M

### 10:00AM **QBIOTICS**

QBiotics Group is an unlisted public company advancing two assets in clinical development across oncology and wound healing. QBiotics' lead asset, tigilanol tiglate, is in phase II trials in soft tissue sarcoma and head & neck cancers. The company's second asset, EBC-1013, is in Phase I trial for the treatment of venous leg ulcers.

### 10:30AM **TELIX PHARMACEUTICALS (TLX)**

Telix Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan.

Market cap \$7.81B



# HEALTHCARE CONFERENCE 2024

## Day 2: Tuesday, 19 November

### 11:00AM **RADIOPHARM THERANOSTICS (RAD)**

Radiopharm Theranostics is a clinical development stage company focused on Radiopharmaceutical Imaging and Therapeutic technologies in Oncology.

Market cap \$52.2M

### 11:30AM **CYCLOPHARM (CYC)**

Cyclopharm is a nuclear medicine company that distributes Technegas, its proprietary lung imaging agent, to over 65 countries. By leveraging off Technegas' recent approval in the USA and expanding indications for use globally, Cyclopharm is entering into a new phase of growth for this globally established med-tech.

Market cap \$152.3M

### 12:00PM **CLARITY PHARMACEUTICALS (CU6)**

Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company developing next-generation theranostic products, based on its platform SAR Technology. The SAR Technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the radiopharmaceutical sector.


Market cap \$2.39B

### 12:30PM **ARGENICA THERAPEUTICS (AGN)**

Argenica Therapeutics is developing novel neuroprotective therapeutics to reduce brain damage after stroke and other devastating brain injuries. The company's lead drug, called ARG-007, is a cationic, arginine rich peptide, currently being evaluated in a randomised Phase 2 clinical trial in acute ischaemic stroke patients.

Market cap \$99.3M

# HEALTHCARE CONFERENCE 2024



**BELL POTTER**

## Day 2: Tuesday, 19 November

1:00PM

### **BOTANIX PHARMACEUTICALS (BOT)**

Botanix Pharmaceuticals is a dermatology company which has received FDA approval for its lead product Sofdra, for the treatment of primary axillary hyperhidrosis. Sofdra is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients.

Market cap \$608.8M

1:30PM

### **SYNTARA (SNT)**

Syntara is a clinical-stage biotechnology company with several ongoing Phase 2 studies for conditions linked to inflammation and fibrosis. The company most advanced asset, called SNT-5505, is being evaluated in patients with the blood cancer myelofibrosis, and is due to report interim data in December 2024.

Market cap \$56.3M

2:00PM

### **MICROBA LIFE SCIENCES (MAP)**

Microba Life Sciences is a microbiome-focussed biotechnology company that provides gut microbiome tests & services and develops novel therapeutic drug candidates. The company's microbiome tests are commercialised in Australia and internationally, either directly by Microba or via leading global distribution partners.

Market cap \$71.7M

2:30PM

### **GENETIC SIGNATURES (GSS)**

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. The company provides PCR based products that allow for the screening of a wide array of infectious diseases.

Market cap \$162.2M

# HEALTHCARE CONFERENCE 2024

## Day 2: Tuesday, 19 November

### 3:00PM MESOBLAST (MSB)

Mesoblast is a world leader in developing allogeneic cellular medicines for the treatment of severe and life-threatening inflammatory conditions. Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocet-L technology platforms.

Market cap \$1.66B

### 3:30PM IMUGENE (IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours.

Market cap \$357.0M

### 4:00PM PARADIGM BIOPHARMACEUTICALS (PAR)

Paradigm Biopharmaceuticals is a late-clinical-stage Phase 3 drug company developing Zilosul®, an effective treatment for the unmet need for osteoarthritis (OA) based upon injectable Pentosan Polysulfate Sodium. The Company's Phase 3 program in knee OA received FDA Fast-Track designation in April 2022.

Market cap \$78.8M

### 4:30PM 4DMEDICAL (4DX)

4DMedical is a software technology company commercialising its patented imaging platform, 'XV Technology'. This four-dimensional lung imaging technology utilises proven, patented mathematic models and algorithms to convert X-ray scans into quantitative data to enhance the capacity of physicians to manage patients with respiratory and lung diseases.

Market cap \$205.6M

# HEALTHCARE CONFERENCE 2024

## Day 2: Tuesday, 19 November

### 5:00PM DOCTOR CARE ANYWHERE (DOC)

Doctor Care Anywhere is one of the UK's largest private providers of telehealth services. The Company works with insurers, healthcare providers and corporate customers to connect patients to a range of digitally enabled telehealth services on its proprietary platform.

Market cap \$25.7M

## Day 3: Wednesday, 20 November

### 9:00AM CYNATA THERAPEUTICS (CYP)

Cynata is a clinical-stage biotechnology company, focussed on the commercialisation of a proprietary induced pluripotent stem cell (iPSC)-based platform technology, Cymerus™. This platform enables scalable manufacture of mesenchymal stem cell (MSC)-based products for therapeutic use. The company has four active clinical programs, with results of three trials expected between 2024-2026.

Market cap \$39.8M

### 9:30AM NEUREN PHARMACEUTICALS (NEU)

Neuren Pharmaceuticals develops novel drugs to treat multiple serious neurological disorders that emerge in early childhood and have no/limited approved treatments. Neuren's lead drug, DAYBUE (trofinetide), is FDA-approved for treatment of Rett syndrome. Neuren's second drug, NNZ-2591, has achieved positive results in multiple Phase 2 trials across Phelan-McDermid, Pitt Hopkins and Angelman syndromes.

Market cap \$2.12B

### 10:00AM IMMUTEP (IMM)

Immutep is a pioneer in developing novel LAG-3 based drug candidates to fight cancer and treat autoimmune diseases. The company's lead asset, called efitlagimod alpha, is undergoing a range of oncology clinical trials, including a global Phase 3 trial in non-small cell lung cancer (NSCLC), that is expected to commence in the coming months.

Market cap \$450.9M

# HEALTHCARE CONFERENCE 2024

## Day 3: Wednesday, 20 November

10:30AM

### MONASH IVF GROUP (MVF)

The Monash IVF Group is a driving force in the development of assisted reproductive technologies and tertiary level prenatal diagnostics. The company has continued to achieve many Australian and world firsts since the achieving the first IVF pregnancy in the world in 1973.

Market cap \$452.0M

11:00AM

### MEDICAL DEVELOPMENTS (MVP)

Medical Developments International is a specialist healthcare company with two key operating segments in analgesia and respiratory devices. The flagship product, Pentrox ('Green Whistle'), is a self-administered, rapid acting non-opioid analgesic which has been used primarily in the pre-hospital care and emergency setting.

Market cap \$50.7M

11:30AM

### EBR SYSTEMS (EBR)

EBR Systems is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The WiSE® CRT System was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management.

Market cap \$376.5M

12:00PM

### LUMOS DIAGNOSTICS (LDX)

Lumos Diagnostics is changing the practice of medicine with the FebriDx point of care test to aid physicians to differentiate bacterial vs nonbacterial infections, aiding the decision to prescribe patients with antibiotics.

Market cap \$23.1M

# HEALTHCARE CONFERENCE 2024

## Day 3: Wednesday, 20 November

1:00PM

### PRO MEDICUS (PME)

Pro Medicus is a healthcare IT company specialising in Enterprise Imaging and Radiology Information System (RIS) software. The company has leading edge products with a growing global presence.

Market cap \$20.97B

1:30PM

### EMVISION MEDICAL DEVICES (EMV)

EMVision Medical Devices is an innovative Australian medical device company developing a novel approach to observing the human body. EMV's product pipeline includes portable, non-invasive, affordable, and safe neurodiagnostic devices. The company's vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies.

Market cap \$165.9M

2:00PM

### AFT PHARMACEUTICALS (AFP)

AFT Pharmaceuticals is a profitable pharmaceutical company with growing sales in over 70 countries and offices in 9 countries. AFT is launching two patented products in the USA and a further launch in China during 2024. A significant number of new products are under development in AFT's R&D pipeline.

Market cap \$269.5M

2:30PM

### MACH7 TECHNOLOGIES (M7T)

Mach7 was designed to meet the imaging needs of the entire healthcare enterprise. The company's platform, solutions, and people are focused on integration, workflow, scalability, and performance to ensure imaging data can be made available wherever it is needed.

Market cap \$94.1M

# HEALTHCARE CONFERENCE 2024

## Day 3: Wednesday, 20 November

3:00PM

### PERCHERON THERAPEUTICS (PER)

Percheron Therapeutics is a late-clinical stage orphan diseases company. The lead asset is ATL1102, which is currently the subject of an international phase IIb randomised clinical trial in Duchenne muscular dystrophy. Initial data is expected in December 2024.

Market cap \$89.2M

3:30PM

### PROTEOMICS (PIQ)

Proteomics International Laboratories is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the industrial scale study of the structure and function of proteins. Proteomics International's vision is to create a world where disease is detected early and cured simply.

Market cap \$93.0M

4:00PM

### CURVEBEAM AI (CVB)

CurveBeam AI is a developer and manufacturer of specialised medical imaging equipment and software aids using image analysis, artificial intelligence and deep learning AI. The flagship product is the HiRise scanner which provides high-resolution 3D imaging facilitating fast scanning with a compact device size.

Market cap \$38.7M

4:30PM

### IMMVIRX

ImmVirX is a private, clinical-stage oncology company developing novel oncolytic viruses to create powerful cancer immunotherapy combinations. The company's lead asset, IVX037, is undergoing a Phase 1 oncology trial, with further agents in preclinical development.

# HEALTHCARE CONFERENCE 2024

Get in touch with your Bell Potter contact for conference access or call 1300 023 557.

Information relayed as part of the Conference is to be considered general investment advice only and does not constitute advice to any person. Although we believe that the advice and information which would be covered and/or provided as part of the Conference is reliable, Bell Potter Securities Limited has not independently verified information which is derived from publicly available sources, directors and management. As such, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information that would be presented as part of the Conference is complete or accurate. Should you wish to consider and implement said information/advice, please assess the appropriateness of this information/advice with regard to your objectives, financial situation and needs, because the advice has not taken these factors into account. Bell Potter Securities Limited does not accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information presented to you as part of the Conference. Although we are elated to host you for another, please note that you are not under any obligation to attend the Conference.